Return to Results

A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer

new search

Trial Conditions
  • Pancreatic Cancer
What is the purpose of this trial?

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Combining gemcitabine with bevacizumab may kill more tumor cells. It is not yet known whether gemcitabine is more effective with or without bevacizumab in treating pancreatic cancer. PURPOSE: This randomized phase III trial is studying gemcitabine and bevacizumab to see how well they work compared to gemcitabine alone in treating patients with locally advanced or metastatic pancreatic cancer.

Date & Status


Who can Participate?


18 and older




- Histologically or cytologically confirmed adenocarcinoma of the pancreas

- Locally advanced or metastatic disease

- Not amenable to curative resection

- No invasion of adjacent organs (e.g., duodenum or stomach) by CT scan

- No evidence of CNS disease, including primary brain tumor or brain metastasis



- 18 and over

Performance status

- ECOG 0-2

Life expectancy

- Not specified


- Granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- No other significant bleeding episodes within the past 6 months


- Bilirubin normal

- SGOT ≤ 2.5 times upper limit of normal (ULN)

- PT and INR ≤ 1.5 times ULN (except for patients on full-dose warfarin)

- No esophageal varices


- Creatinine ≤ 1.5 mg/dL OR

- Creatinine clearance ≥ 60 mL/min

- No proteinuria

- Patients with ≥ 1+ proteinuria must demonstrate < 1 g/dL of protein on 24-hour
urine collection


- No clinically significant cardiovascular disease

- No uncontrolled hypertension (i.e., blood pressure > 150/90 mm Hg on medication)

- No arterial thromboembolic event within the past 6 months, including any of the

- Myocardial infarction

- Unstable angina pectoris

- Cerebrovascular accident

- Transient ischemic attack

- No New York Heart Association grade II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No peripheral vascular disease ≥ grade 2

- No clinically significant peripheral artery disease (i.e., claudication on < 1 block)


- No hemoptysis within the past 6 months


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for up to 3 months after
study participation

- No upper or lower gastrointestinal bleeding within the past 6 months

- No serious or non-healing wound, ulcer, or bone fracture

- No serious active viral, fungal, or bacterial infection

- No infection requiring parenteral antibiotics

- No hypersensitivity to Chinese hamster ovary cell products or other recombinant

- No significant traumatic injury within the past 28 days

- No other active malignancy except nonmelanoma skin cancer


Biologic therapy

- No prior bevacizumab in the adjuvant or metastatic setting

- No other prior vascular endothelial growth factor inhibitors

- No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)

- No concurrent pegfilgrastim


- See Radiotherapy

- More than 4 weeks since prior adjuvant chemotherapy and recovered

- Patients must have evidence of disease progression after adjuvant chemotherapy

- No prior chemotherapy for metastatic disease

- No prior gemcitabine in the adjuvant or metastatic setting

- No other concurrent chemotherapy agents

Endocrine therapy

- No concurrent hormones except steroids for adrenal failure, hormones for
non-disease-related conditions (e.g., insulin for diabetes), or intermittent
dexamethasone as an antiemetic


- Prior radiotherapy with or without a radiosensitizing dose of fluoropyrimidines
allowed provided there is disease outside radiotherapy port

- At least 4 weeks since prior radiotherapy and recovered

- No concurrent palliative radiotherapy


- More than 28 days since prior major surgical procedure or open biopsy

- More than 7 days since prior fine needle aspirations

- No concurrent major surgical procedures


- More than 1 month since prior thrombolytic agent

- No concurrent thrombolytic agent

- Concurrent full-dose anticoagulants allowed provided the patient is maintained on a
stable dose of warfarin with an in-range INR (between approximately 2-3) OR on a
stable dose of low molecular weight heparin

Gender: Both
Steward Physician(s)
  • Hedy L. Kindler, MD
Trial Interventions
  • bevacizumab
  • gemcitabine hydrochloride
Physician Researcher

Investigator Name:

  • Hedy L. Kindler, MD

Other Information

Sponsor: Cancer and Leukemia Group B
Phase: Phase 3
Trial ID: NCT00088894
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions